Extended follow-up on KEYNOTE-024 suggests significant survival benefit for pembrolizumab in patients with PD-L1 =50%, but unanswered questions remain.
Pacheco JM, Gao D, Camidge DR. Extended follow-up on KEYNOTE-024 suggests significant survival benefit for pembrolizumab in patients with PD-L1 =50%, but unanswered questions remain. Ann Transl Med. 2019 Jul; 7(Suppl 3):S127.